Stéphanie Longet, PhD

​Novel intranasal vaccine strategies against respiratory viruses

​

Systemic vaccines against respiratory viruses such as influenza or SARS-CoV-2 are very efficient to protect from severe diseases. However, they are less efficient against infection. In addition to the evolution of viruses, a weakness is the low and/or short-term mucosal responses induced by systemic vaccination. Intranasal vaccination is a way to improve respiratory responses. We will develop a novel intranasal vaccine platform against respiratory viruses.

​

Characterization of tissue-resident memory responses in mucosal tissues

​

One of main challenge of mucosal vaccination including intranasal vaccination, is to induce long-term mucosal memory responses. Mucosal tissue-resident memory T and B cells have shown to be key in long-term protection at mucosal surfaces. We will characterize tissue-resident memory T and B cells induced by respiratory infections.

​

Adjuvants to induce mucosal tissue-resident memory responses

​

We will tailor our intranasal vaccine strategies to enhance the development and maintenance of tissue-resident memory T and B cells in airway tissues. We will also screen adjuvants which can improve tissue-resident memory responses in airway tissues.

​